Table 4.

Number of tests required per omitted adjuvant chemotherapy per tumor characteristic (tumor grade, proliferation Ki67and T tumor size) and additional benefit of chemotherapy (%) on 10-year recurrence-free survival (rfs) based on NHS Predict score. * Ki67 pathology lab specific limits are presented in Table 1.

	Number of Patients Omitted Chemo	Number of ProSigna Tests	ROR Risk Category			Number of Tests Needed to Avoid One Chemotherapy Treatment
			High	Intermediate	Low
All patients	118	360	56	153	146	3.1
Grade
2	105	285	29	127	129	2.7
3	13	63	29	26	-	4.8
Ki67
Low *	3	27	0	3	29	9.0
Intermediate *	23	99	3	33	57	4.3
High *	93	234	56	118	61	2.5
T1 ≤ 20mm	77	244	34	111	99	3.2
T2 > 20mm	40	113	25	43	48	2.8
Predict chemo benefit (10 year rfs)
0–3%	80	283	33	123	127	3.5
3–6%	33	64	19	27	18	1.9
6–9%	4	13	7	4	2	3.3
Grade 2, T >10 mm	105	256	26	112	117	2.4
Grade 2, T >10 mm, Low Ki67	5	26	-	3	23	5.2
Grade 2, T >10 mm, Intermediate Ki67	19	86	3	32	51	4.5
Grade 2, T >10 mm, High Ki67	81	144	24	77	43	1.8